Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifapentine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 3/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.87 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.87 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.87 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.87 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifapentine SCHEMBL29448246 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL29913543 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL29359039 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL18842901 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL20032589 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL41590 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL20033121 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL15472877 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL20769769 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA | |
| Rifapentine SCHEMBL25876809 | 1.00 | MAPT (1.00) | MAPTABCB11ABCC4ABCC2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13480 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075482-A | Use of rifamycin in the treatment of colorectal cancer | — | 2026-05-26 | — | — | CN | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-20260109712-A1 | RIFAMYCINS FOR NONTUBERCULOUS MYCOBACTERIA | UNIV MINNESOTA (US) | 2026-04-23 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4727950-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2026-04-22 | — | — | EP | claimed |
| US-12589127-B2 | Bacteriophages for treatment of tuberculosis | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2026-03-31 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | SCRIPPS RESEARCH INST (US) | 2026-02-19 | — | — | US | claimed |
| EP-4121058-B1 | OXAZOLIDINONE COMPOUND AND ITS USE THEREOF AS AN ANTIBACTERIAL AGENT | MERCK SHARP & DOHME LLC (US) | 2026-02-18 | — | — | EP | claimed |
| CN-1134278-A | Aerosol for preventing and curing pulmonary tuberculosis and its preparing method and synergy method | CONG FANZI (CN) | 1996-10-30 | — | — | CN | claimed |
| EP-0536197-B1 | PURE CRYSTALLINE FORM OF RIFAPENTINE | LEPETIT SPA (IT) | 1995-07-26 | — | — | EP | claimed |
| CN-1098912-A | Carbohydrate for curing gonorrhea | FU MIN (CN) | 1995-02-22 | — | — | CN | claimed |
| EP-0440642-B1 | RIFAPENTINE HYDROHALIDES | LEPETIT SPA (IT) | 1994-09-07 | — | — | EP | claimed |
| US-5306715-A | Storage stability | GRUPPO LEPETIT SPA (IT) | 1994-04-26 | — | — | US | claimed |
| EP-0536197-A1 | PURE CRYSTALLINE FORM OF RIFAPENTINE. | LEPETIT SPA (IT) | 1993-04-14 | — | — | EP | claimed |
| WO-1992000302-A1 | PURE CRYSTALLINE FORM OF RIFAPENTINE | GRUPPO LEPETIT S.P.A. (IT) | 1992-01-09 | — | — | WO | claimed |
| EP-0440642-A1 | RIFAPENTINE HYDROHALIDES. | LEPETIT SPA (IT) | 1991-08-14 | — | — | EP | claimed |
| CN-1039421-A | RIFAPENTINE HYDROHALIDES | LEPETIT SPA (IT) | 1990-02-07 | — | — | CN | claimed |
| WO-1990000553-A1 | RIFAPENTINE HYDROHALIDES | GRUPPO LEPETIT S.P.A. (IT) | 1990-01-25 | — | — | WO | claimed |